NCT01446991View on ClinicalTrials.gov

Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

February 28, 2017

Study Completion Date

December 31, 2017

Conditions
Prostate Cancer
Interventions
DRUG

Degarelix

240 mg loading dose followed by monthly 80 mg maintenance dose for 2-3 months

DRUG

Degarelix

240 mg loading dose of Degarelix followed by 80 mg maintenance doses every month for a total duration of 6 months.

Trial Locations (3)

Unknown

Abbottsford Cancer Center, Abbottsford

Fraser Valley Cancer Center, Surrey

V5Z4E6

Vancouver Cancer Center, Vancouver

All Listed Sponsors
lead

British Columbia Cancer Agency

OTHER

NCT01446991 - Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy | Biotech Hunter | Biotech Hunter